GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HKSE:04332) » Definitions » Notes Receivable

Amgen (HKSE:04332) Notes Receivable : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Amgen Notes Receivable?

Amgen's Notes Receivable for the quarter that ended in Dec. 2023 was HK$0 Mil.


Amgen Notes Receivable Historical Data

The historical data trend for Amgen's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Notes Receivable Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Amgen Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Amgen Notes Receivable Related Terms

Thank you for viewing the detailed overview of Amgen's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (HKSE:04332) Business Description

Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (HKSE:04332) Headlines

No Headlines